Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Ying Cheng,David R Spigel,Byoung Chul Cho,Konstantin K Laktionov,Jian Fang,Yuanbin Chen,Yoshitaka Zenke,Ki Hyeong Lee,Qiming Wang,Alejandro Navarro,Reyes Bernabe,Eva Lotte Buchmeier,John Wen-Cheng Chang,Yoshimasa Shiraishi,Sema Sezgin Goksu,Andrzej Badzio,Anhui Shi,Davey B Daniel,Nguyen Thi Thai Hoa,Milada Zemanova,Helen Mann,Hema Gowda,Haiyi Jiang,Suresh Senan,ADRIATIC Investigators,Facundo Rufino Caminos,Ignacio Casarini,Juan Cundom,Andrea Pastor,Karina Vera,Frank Aboubakar Nana,Kristof Cuppens,Ingel Demedts,Bogdan Grigoriu,Thierry Pieters,Piet Vercauter,Shantanu Banerji,Stephanie Brule,Quincy Chu,Mark Doherty,Peter Ellis,Alexander Louie,David Palma,Paul Wheatley-Price,Baoshan Cao,Yuan Chen,Zhendong Chen,Yuzhong Duan,Zhiyong He,Zhouguang Hui,Hao Jiang,Liyan Jiang,Tao Li,Xiaoling Li,Yunpeng Liu,Hungda Lu,Shun Lu,Rui Meng,Buhai Wang,Dong Wang,Mengzhao Wang,Qifeng Wang,Lin Wu,Mingjun Zhang,Lujun Zhao,Jianya Zhou,Zhengfei Zhu,Marketa Cernovska,Libor Havel,Bohdan Kadlec,Vitezslav Kolek,Juraj Kultan,Jaromir Roubec,Juergen Alt,Eva Buchmeier,Maike de Wit,Walburga Engel-Riedel,Frank Griesinger,Jens Kern,Hans-Georg Kopp,Christian Lerchenmueller,Justyna Rawluk,Niels Reinmuth,Christian Schulz,Erich Stoelben,Michael Thomas,Hari Goyal,Mohit Saxena,Satheesh Chiradoni Thungappa,Paolo Borghetti,Sergio Bracarda,Filippo de Marinis,Roberto Ferrara,Maria Antonietta Gambacorta,Marina Chiara Garassino,Giovanna Mantini,Silvia Novello,Claudia Proto,Marcello Tiseo,Vincenzo Valentini,Keisuke Aoe,Shinji Atagi,Koichi Azuma,Tetsunari Hase,Hidetoshi Hayashi,Toyoaki Hida,Atsushi Horiike,Yoshitsugu Horio,Yukio Hosomi,Shoichi Kuyama,Haruyasu Murakami,Seiji Niho,Makoto Nishio,Hiroshi Nokihara,Hirokazu Ogino,Yuichiro Ohe,Satoshi Oizumi,Isamu Okamoto,Kyoichi Okishio,Shunichi Sugawara,Masayuki Takeda,Hiroshi Tanaka,Bonne Biesma,Lisenka Boom,Steven Gans,Sayed Hashemi,Birgitta Hiddinga,Ewa Chmielowska,Izabella Dębicka,Marcin Golecki,Jaroslaw Kolb-Sielecki,Dariusz Kowalski,Mikhail Dvorkin,Alexander Fedenko,Sergey Gamayunov,Nadezhda Kovalenko,Konstantin Laktionov,Fagim Mufazalov,Guzel Mukhametshina,Madina Ramazanova,Nailya Sherman,Vitaliy Skoropad,Alexey Smolin,Galina Statsenko,Vladimir Usachev,Anastasia Zimina,Jin Hyuk Choi,Ji-Youn Han,Jun Ho Ji,Dong-Wan Kim,Sang-We Kim,Sung Min Kim,Yu Jung Kim,Gyeong-Won Lee,Jong Seok Lee,Kyung Hee Lee,Yong Pyo Lee,Edurne Arriola,Manuel Domine,Pilar Garrido,Dolores Isla,Oscar Juan,Maria Eugenia Olmedo,Luis Paz-Ares,Pedro Filipe Simões da Rocha,Noemi Villanueva,Gee-Chen Chang,Chao-Hsun Chen,Chung-Yu Chen,Yuh-Min Chen,Chung-Ching Hua,Jen-Chung Ko,Wei-Ke Kuo,Kang-Yun Lee,Chien-Chung Lin,Wu-Chou Su,Chin-Chou Wang,Tsung-Ying Yang,Ahmet Alacacioglu,Mehmet Artac,Irfan Cicin,Timucin Cil,Hasan Senol Coskun,Guzin Demirag,Mustafa Erman,Mustafa Özgüroğlu,Sernaz Topaloğlu,Ulku Yilmaz,Laura Cove-Smith,Grant Stewart,Ali Amjad,Ian Anderson,Susanne Arnold,Hossein Borghaei,Jeremy Cetnar,Anne Chiang,Cheryl Czerlanis,Davey Daniel,Ari Elman,Anna Farago,Charles Farber,Charlene Fares,Justin Gainor,Adam Goldrich,Missak Haigentz Jr,Christine Hann,Basir Haque,Wade Iams,Puneeth Iyengar,Steven Jubelirer,Fadi Kayali,Ahmed Khalid,Joseph Leach,Steven McCune,Manuel Modiano,Misako Nagasaka,Santosh Nair,Shetal Patel,Vipul Patel,Ahad Sadiq,Nitika Sharma,David Spigel,Christian Squillante,Thomas Stanton,Kevin Sullivan,Christopher Sumey,Imad Tabbara,Jonathan Thompson,Khaled Tolba,Michaela Tsai,Dipesh Uprety,Ashley Weiner,Kenneth Westover,Deng Zhang,Dang Van Khiem,Ha Le Nguyen,Thi Thai Hoa,Nguyen Tuan Khoi,Nguyen Van Do,Huong Tran
DOI: https://doi.org/10.1056/NEJMoa2404873
2024-10-10
Abstract:Background: Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy. Methods: In a phase 3, double-blind, randomized, placebo-controlled trial, we assigned patients to receive durvalumab at a dose of 1500 mg, durvalumab (1500 mg) plus tremelimumab at a dose of 75 mg (four doses only), or placebo every 4 weeks for up to 24 months. Randomization was stratified according to disease stage (I or II vs. III) and receipt of prophylactic cranial irradiation (yes vs. no). Results of the first planned interim analysis of the two primary end points of overall survival and progression-free survival (assessed on the basis of blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1) with durvalumab as compared with placebo (data cutoff date, January 15, 2024) are reported; results in the durvalumab-tremelimumab group remain blinded. Results: A total of 264 patients were assigned to the durvalumab group, 200 to the durvalumab-tremelimumab group, and 266 to the placebo group. Durvalumab therapy led to significantly longer overall survival than placebo (median, 55.9 months [95% confidence interval {CI}, 37.3 to not reached] vs. 33.4 months [95% CI, 25.5 to 39.9]; hazard ratio for death, 0.73; 98.321% CI, 0.54 to 0.98; P = 0.01), as well as to significantly longer progression-free survival (median 16.6 months [95% CI, 10.2 to 28.2] vs. 9.2 months [95% CI, 7.4 to 12.9]; hazard ratio for progression or death, 0.76; 97.195% CI, 0.59 to 0.98; P = 0.02). The incidence of adverse events with a maximum grade of 3 or 4 was 24.4% among patients receiving durvalumab and 24.2% among patients receiving placebo; adverse events led to discontinuation in 16.4% and 10.6% of the patients, respectively, and led to death in 2.7% and 1.9%. Pneumonitis or radiation pneumonitis with a maximum grade of 3 or 4 occurred in 3.1% of the patients in the durvalumab group and in 2.6% of those in the placebo group. Conclusions: Adjuvant therapy with durvalumab led to significantly longer overall survival and progression-free survival than placebo among patients with limited-stage small-cell lung cancer. (Funded by AstraZeneca; ADRIATIC ClinicalTrials.gov number, NCT03703297.).